NCT06634589 2026-04-15A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesBeOne MedicinesPhase 1/2 Recruiting80 enrolled